Global Basal Cell Carcinoma Market to Surpass US$ 11,458.3 Million by 2028, Says Coherent Market Insights (CMI)

Pune, INDIA


SEATTLE, Dec. 07, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global basal cell carcinoma market is estimated to be valued at US$ 6,721.4 million in 2021 and is expected to exhibit a CAGR of 7.9% during the forecast period (2021-2028).

Key Trends and Analysis of the Global Basal Cell Carcinoma Market:

Key trends in the market include product approval for treatment of basal cell carcinoma, which is expected to drive the market growth over the forecast period. For instance, in June 2020, Sun Pharmaceutical Industries Ltd, manufactures and markets pharmaceuticals for domestic and international distribution, announced that the U.S. Food and Drug Administration (FDA) had approved its two specialty medicines-ODOMZO (sonidegib) and LEVULAN KERASTICK (aminolevulinic acid HCl) + BLU-U from its dermatology portfolio. The company provides insights to the healthcare providers treating patients suffering from high risk for different types of cancers.

Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4794

Key Market Takeaways:

The global basal cell carcinoma market is expected to exhibit a CAGR of 7.9% during the forecast period, due to increasing geriatric population which is expected to drive the global basal cell carcinoma market over the forecast period. For instance, according to the World Health Organization (WHO), population aged 60 years and above is likely to rise from 900 million in 2015 to 2 billion in 2050 worldwide.

Among treatment type, surgical segment is estimated to hold a dominant position in the global basal cell carcinoma market in 2021, owing to increasing demand for efficient and quicker treatment methods which is done with the help of surgeries. For instance, according to the American Academy of Dermatology, it is estimated that 196,060 new cases of melanoma, 101,280 noninvasive (in situ), and 106,110 invasive, will be diagnosed in the U.S. in 2021.

On the basis of region, North America segment accounted for the largest market share in the global basal cell carcinoma market over the forecast period, due to increasing health care expenditure. For instance, according to data published in the Canadian Institute for Health Information, on November 4, 2021, Canada is expected to spend a new record of US$ 308 billion on healthcare in 2021. Moreover, new data from the Canadian Institute for Health Information (CIHI) shows that total expenditure on health is expected to have increased by over 12% between 2019 and 2020. This is triple the growth rate experienced from 2015 to 2019, which was steady at approximately 4% per year.

Purchase this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4794

Competitive Landscape:

Key players operating in the global basal cell carcinoma market include Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Novartis AG., Bausch & Lomb Incorporated., Allergan, Perrigo Company plc, Taro Pharmaceutical Industries Ltd., Provectus Biopharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sanofi, and Mylan N.V.

Market segmentation:

  • Global Basal Cell Carcinoma Market, By Treatment Type :
    • Surgical
      • Surgical Excision
      • Electrodessication & Cutterage ED&C
      • Moh's Surgery
      • Cryosurgery
    • Drugs
      • Topical Treatment
      • Advanced Medication
      • Other
    • Others
      • Radiation Therapy
      • Photodynamic Therapy PDT
      • Laser Therapy
  • Global Basal Cell Carcinoma Market, By End User :
      • Hospitals
      • Specialty Clinics
      • Others
  • Global Basal Cell Carcinoma Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa


Related Market Intelligence Reports:

Immune Checkpoint Inhibitors Market by Drug Class (Programmed Death Receptor-1 (PD-1) Inhibitors (Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Others (Spartalizumab), Programmed Death-Ligand 1 (PD-L1) Inhibitors (Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi)), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) Inhibitors (Ipilimumab (Yervoy)), Indoleamine-2,3-dioxygenase (IDO) Inhibitors, Lymphocyte-Activation Gene 3 Inhibitors)), By Cancer Type (Lung Cancer, Head & Neck Cancers, Skin Cancer (Melanoma and Merkel Cell Carcinoma), Blood Cancer (Lymphoma), Bladder Cancer (Urothelial Carcinoma), Renal/Kidney Cancer, Colorectal Cancer, Breast Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),  and region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Bile Duct Cancer Market, by Treatment Type (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine and 5 fluorouracil (5-FU), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), and Ivosidenib (Phase 3), Immunotherapy (Pembrolizumab (Phase 3) and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028


About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Follow Us: LinkedInTwitter

 

Coordonnées